Neurogene (NGNE) AI Stock Analysis

• Market Cap: $162.58M
• Dividend Yield: N/A
• Average Volume (3M): 327.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.50
• Revenue Growth: N/A
• EPS Growth: -140.77%
• Country: US
• Employees: 107
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -4.60
• Shares Outstanding: 14,929,566
• 10 Day Avg. Volume: 492,918
• 30 Day Avg. Volume: 327,750
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 228.20
• Price to Cash Flow (P/CF): -3.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $44.40
• Price Target Upside: 290.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

Neurogene faces significant financial challenges typical of early-stage biotech firms, with no revenue and substantial losses. The technical analysis indicates a bearish trend, exacerbating concerns about stock performance. Valuation metrics are weak due to negative earnings, although recent corporate developments in their NGN-401 program present a potential long-term positive outlook if successful.

Positive Factors

Clinical Development

NGN-401 has shown impressive efficacy and a tolerable safety profile.

Financial Stability

Neurogene has sufficient cash to provide a runway extending through the NGN-401 pivotal trial.

Regulatory Designation

NGN-401 has received Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).

Negative Factors

Adverse Events

High-dose NGN-401 led to treatment-related serious adverse events and other high-dose patients experienced Grade 2 and 3 treatment-emergent adverse events.

Clinical Risks

Risks include potential delays in advancing candidates and the possibility of not generating favorable clinical data, particularly for NGN-401 in Rett syndrome.

Neurogene Business Overview & Revenue Model

Company Description

Neurogene (NGNE) is a biotechnology company focused on developing life-changing genetic medicines to address severe neurological diseases. The company operates within the healthcare and biotechnology sectors, leveraging cutting-edge gene therapy techniques to create innovative treatments that have the potential to transform patient outcomes.

How the Company Makes Money

Neurogene makes money primarily through the development and commercialization of its gene therapy products. The company's revenue streams include licensing agreements, where it partners with larger pharmaceutical companies to co-develop and market its therapies, and potential sales of approved treatments. Neurogene may also receive funding through research grants, collaborations with academic institutions, and milestone payments from its strategic partnerships, which support its ongoing research and development efforts.

Neurogene Financial Statement Overview

Summary

Neurogene's financial health reflects the typical challenges of early-stage biotech firms, with no revenue and high R&D expenses leading to substantial losses. Cash reserves provide short-term stability, but reliance on external financing and past negative equity highlight financial vulnerabilities.

Income Statement

Neurogene has consistently reported zero revenue over the years, highlighting the early-stage nature of its research-focused operations. The company faces substantial net losses, which have increased over time, indicating high operating expenses without corresponding income. This consistent lack of revenue and growing net losses reflect significant financial challenges.

Balance Sheet

The balance sheet shows a strong liquidity position with significant cash reserves compared to total debt, evidenced by healthy net debt figures. However, the company's equity ratio has been negative in recent years due to significant accumulated losses, although it turned positive in 2023 and 2024. The high cash position provides some stability, but the negative equity in the past highlights financial distress.

Cash Flow

Neurogene's cash flow statements indicate negative operating and free cash flows, consistent with its status as a pre-revenue biotech firm. The company relies heavily on financing activities for cash inflows, which is unsustainable long-term. While free cash flow has improved marginally, the negative cash flow from operations poses a significant risk.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
925.00K	0.00	0.00	0.00	0.00
	Gross Profit
925.00K	-3.26M	-3.20M	-2.28M	-1.82M
	EBIT
-82.61M	-55.58M	-56.52M	-50.53M	-41.55M
	EBITDA
-71.89M	-52.29M	-51.99M	-49.59M	-31.46M
	Net Income Common Stockholders
-75.14M	-36.32M	-55.19M	-50.52M	-33.28M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
312.40M	197.16M	82.02M	70.54M	192.56M
	Total Assets
335.73M	222.57M	109.27M	101.49M	210.52M
	Total Debt
12.43M	16.25M	4.69M	5.21M	12.12M
	Net Debt
-124.16M	-131.96M	-77.33M	-65.33M	-180.43M
	Total Liabilities
25.36M	36.55M	255.00M	193.36M	19.30M
	Stockholders Equity
310.38M	186.02M	-145.74M	-91.88M	191.22M
Cash Flow		Free Cash Flow
-71.41M	-51.74M	-55.05M	-64.77M	-26.79M
	Operating Cash Flow
-70.60M	-51.42M	-52.82M	-46.40M	-24.57M
	Investing Cash Flow
-125.26M	25.64M	-2.23M	-18.37M	-2.22M
	Financing Cash Flow
184.07M	92.48M	66.53M	51.06M	77.14M

Neurogene Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NGNE, the sentiment is Negative. The current price of 11.36 is below the 20-day moving average (MA) of 11.79, below the 50-day MA of 15.36, and below the 200-day MA of 30.24, indicating a bearish trend. The MACD of -1.67 indicates Negative momentum. The RSI at 45.11 is Neutral, neither overbought nor oversold. The STOCH value of 86.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NGNE.

Neurogene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
KRRO	46 Neutral	$120.55M	―	-50.61%	―	―	85.19%
PRQR	41 Neutral	$124.15M	―	-43.72%	―	190.40%	7.54%
LYEL	40 Underperform	$131.28M	―	-66.10%	―	-53.08%	-40.31%
IKT	31 Underperform	$148.68M	―	-52.00%	―	-100.00%	38.72%
NGNE	30 Underperform	$162.58M	―	-30.28%	―	―	-140.77%
FDMT	27 Underperform	$128.72M	―	-25.95%	―	―	―

Neurogene Corporate Events

Neurogene Highlights Progress in Rett Syndrome Program

Neurogene has updated its corporate presentation, highlighting the progress and future plans for its NGN-401 program for Rett syndrome, which is currently in Phase 1/2 clinical trials. The company is leveraging its proprietary EXACT technology and in-house manufacturing to advance its pipeline and explore market opportunities, positioning itself strategically in the biopharmaceutical sector.